Antibodies against T cell checkpoint molecules have started to revolutionize cancer
treatment. Nevertheless, less than half of all patients respond to these immunotherapies.
Recent work supports the potential value of biomarkers that predict therapy outcome and
inspires the development of assay systems that interrogate other aspects of the cancer-
immunity cycle.